PRA Health Sciences Inc. (NASDAQ:PRAH) – Analysts at William Blair lifted their FY2016 EPS estimates for PRA Health Sciences in a research note issued to investors on Monday. William Blair analyst J. Kreger now anticipates that the firm will post earnings per share of $2.39 for the year, up from their previous forecast of $2.38.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $0.64 EPS for the quarter, hitting analysts’ consensus estimates of $0.64. The firm earned $399.80 million during the quarter, compared to analyst estimates of $394.87 million. PRA Health Sciences had a return on equity of 21.25% and a net margin of 4.86%. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.52 EPS.

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

PRAH has been the topic of a number of other reports. Credit Suisse Group AG reaffirmed a “hold” rating and set a $50.00 price objective on shares of PRA Health Sciences in a research note on Thursday, November 3rd. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $54.00 price objective on the stock in a research note on Wednesday, August 3rd. TheStreet raised PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Monday, November 14th. KeyCorp reissued a “buy” rating on shares of PRA Health Sciences in a research note on Friday, November 4th. Finally, Jefferies Group reissued a “buy” rating on shares of PRA Health Sciences in a research note on Tuesday, September 13th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. PRA Health Sciences has an average rating of “Buy” and a consensus price target of $55.86.

Shares of PRA Health Sciences (NASDAQ:PRAH) opened at 54.99 on Wednesday. The firm’s 50-day moving average price is $55.02 and its 200-day moving average price is $49.62. The company has a market capitalization of $3.38 billion, a price-to-earnings ratio of 42.69 and a beta of 0.61. PRA Health Sciences has a one year low of $35.60 and a one year high of $60.96.

Hedge funds have recently modified their holdings of the company. Fisher Asset Management LLC raised its stake in shares of PRA Health Sciences by 2.5% in the second quarter. Fisher Asset Management LLC now owns 5,244 shares of the company’s stock valued at $225,000 after buying an additional 127 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of PRA Health Sciences by 7.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,025 shares of the company’s stock valued at $114,000 after buying an additional 133 shares during the period. Acrospire Investment Management LLC raised its stake in shares of PRA Health Sciences by 8.7% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the company’s stock valued at $104,000 after buying an additional 200 shares during the period. Ngam Advisors L.P. raised its stake in shares of PRA Health Sciences by 0.4% in the third quarter. Ngam Advisors L.P. now owns 53,027 shares of the company’s stock valued at $2,996,000 after buying an additional 228 shares during the period. Finally, FDx Advisors Inc. raised its stake in shares of PRA Health Sciences by 6.3% in the second quarter. FDx Advisors Inc. now owns 5,154 shares of the company’s stock valued at $215,000 after buying an additional 305 shares during the period.

TRADEMARK VIOLATION NOTICE: “Analysts Set Expectations for PRA Health Sciences Inc.’s FY2016 Earnings (PRAH)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/25/analysts-set-expectations-for-pra-health-sciences-inc-s-fy2016-earnings-prah.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

5 Day Chart for NASDAQ:PRAH

Receive News & Stock Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related stocks with our FREE daily email newsletter.